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Cannabinoid receptor 2 agonist attenuates pain
related behavior in rats with chronic alcohol/high
fat diet induced pancreatitis
Liping Zhang1, Robert H Kline IV1, Terry A McNearney2, Michael P Johnson2 and Karin N Westlund1*
Abstract
Background: Chronic Pancreatitis (CP) is a complex and multifactorial syndrome. Many contributing factors result in
development of dysfunctional pain in a significant number of patients. Drugs developed to treat a variety of pain
states fall short of providing effective analgesia for patients with chronic pancreatitis, often providing minimal to
partial pain relief over time with significant side effects. Recently, availability of selective pharmacological tools has
enabled great advances in our knowledge of the role of the cannabinoid receptors in pathophysiology. In particular,
cannabinoid receptor 2 (CB2) has emerged as an attractive target for management of chronic pain, as demonstrated in
several studies with inflammatory and neuropathic preclinical pain models. In this study, the analgesic efficacy of a
novel, highly selective CB2 receptor agonist, LY3038404 HCl, is investigated in a chronic pancreatitis pain model,
induced with an alcohol/high fat (AHF) diet.
Results: Rats fed the AHF diet developed visceral pain-like behaviors detectable by week 3 and reached a maximum at
week 5 that persists as long as the diet is maintained. Rats with AHF induced chronic pancreatitis were treated with
LY3038404 HCl (10 mg/kg, orally, twice a day for 9 days). The treated animals demonstrated significantly alleviated pain
related behaviors after 3 days of dosing, including increased paw withdrawal thresholds (PWT), prolonged abdominal
withdrawal latencies (ABWL), and decreased nocifensive responses to noxious 44°C hotplate stimuli. Terminal histological
analysis of pancreatic tissue sections from the AHF chronic pancreatitis animals demonstrated extensive injury, including
a global pancreatic gland degeneration (cellular atrophy), vacuolization (fat deposition), and fibrosis. After the LY3038404
HCl treatment, pancreatic tissue was significantly protected from severe damage and fibrosis. LY3038404 HCl affected
neither open field exploratory behaviors nor dark/light box preferences as measures of higher brain and motor functions.
Conclusion: LY3038404 HCl, a potent CB2 receptor agonist, possesses tissue protective and analgesic properties without
effects on higher brain function. Thus, activation of CB2 receptors is suggested as a potential therapeutic target for
visceral inflammation and pain management.
Keywords: Alcohol, CB2, Pain, Ki67, Hyperalgesia, Pancreas, Behavioral testing, 44°C hotplate test, Tissue repair, High fat
Background
Chronic Pancreatitis (CP) is a complex and multifactorial
syndrome. Many contributing factors can result in abnormal
pain etiology, including both peripheral and central pain
processing and structural abnormalities of the pancreatic
gland [1]. The higher incidence in men reported nationally
is attributed not only to alcohol and tobacco abuse as
risk factors, but a genetic prevalence in men to have
the CLDN2 risk factor DNA variant with alcohol associated
chronic pancreatitis (47%) [2-5]. Pain management in
CP is challenging and often leads to time-consuming
and unsatisfactory approaches to treatment with an
unpredictable outcome. Despite the availability of analgesics
approved for chronic or neuropathic pain, current analgesics
only provide partial pain relief and/or produce significant
side effects. Recently, availability of selective pharmacological
tools has enabled great advance of our knowledge of the role
of cannabinoid receptor 2 (CB2) in pathophysiology. The
cannabinoid receptors are a class of cell membrane receptors
under the G protein-coupled receptor superfamily. There are
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currently two known subtypes, termed CB1 and CB2.
The CB1 receptors are expressed mainly in the brain
(central nervous system or "CNS"), but also in the
lungs, liver and kidneys. CB2 receptors are largely
restricted to immune and hematopoetic cells, although
functionally relevant expression has been found in specific
regions of the brain and in myocardium, gut, endothelial,
vascular smooth muscle and Kupffer cells, exocrine and
endocrine pancreas, bone, reproductive organs/cells, and
in various tumors [6-9]. Evidence suggests that there
are novel cannabinoid receptors, that is, non-CB1 and
non-CB2, which are expressed in endothelial cells and
in the CNS [10].
Initially the interest in cannabinoid receptors as potential
targets for chronic pain was limited to cannabinoid recep-
tor 1 (CB1), with the aim of identifying an agonist suitable
for drug development. Unfortunately analgesia induced by
CB1 agonists is associated with undesirable central nervous
system side effects which have hampered their progress for
therapeutic development [11]. More recently, the type 2
cannabinoid receptor (CB2) has emerged as an interesting
target alternative to CB1. Its expression is upregulated in
response to tissue or nerve injury, and in preclinical pain
models the activation of this receptor induces significant
analgesia without overt side effects [12,13].
The most likely cellular targets and executors of the
CB2 receptor-mediated effects of endocannabinoids or
synthetic agonists are proposed to be the immune and
immune-derived cells (e.g. leukocytes, various populations
of T and B lymphocytes, monocytes/macrophages, dendritic
cells, mast cells, microglia in the brain, Kupffer cells in the
liver, etc.). However, the number of other potential cellular
targets is expanding, now including epithelial, endothelial
and smooth muscle cells, fibroblasts of various origins,
cardiomyocytes, and certain neuronal elements of the
peripheral or central nervous systems [7,14-16]. In
the brain, CB2 receptors are predominately expressed
by microglial cells, where their role remains unclear
[7,12,14,15,17,18] but is suggestive of an anti-inflammatory
role. In particular, CB2 for chronic pain treatment has
been successfully demonstrated by several studies with
inflammatory and neuropathic preclinical pain models
[19,20]. While the CB2 receptors are involved in mediating
analgesic effects in the peripheral nervous system, these
receptors are not expressed by nociceptive sensory neurons
[7]. At present CB2 receptors are believed to exist on
an undetermined, non-neuronal cell in the vicinity of
peripheral nerve terminals. Possible candidates in the
pancreas include mast cells and innate immune stellate
cells which are known to facilitate the inflammatory
response. Cannabinoid mediated inhibition of these
responses may be caused by a decrease in the receptor
perception of noxious stimuli [10,21,22]. Recent studies
showed that CB1 and CB2 are also expressed on pancreatic
acinar cells, and the relatively nonselective CB1/CB2
agonist HU210 ameliorates acute experimental pancreatitis
by systemic administration [23]. During acute pancreatitis,
an upregulation especially of CB2 on apoptotic cells has
been shown, and activation of cannabinoid receptor 2
attenuated the acute pancreatitis [24]. Little is known
about the effects of CB2 that impact inflammation and
pain in chronic pancreatitis.
In the present study, a novel CB2 receptor agonist
LY3038404 HCl was evaluated for therapeutic efficacy in
the AHF chronic pancreatitis rat model. The major
finding of the present study is that the potent CB2
receptor agonist LY3038404 HCl possesses tissue protection
and analgesic properties. No side effects on higher brain
function were observed. Thus, activation of CB2 receptors
is suggested as a potential therapeutic target for visceral
inflammation and pain management.
Results and discussion
AHF diet induced chronic pancreatitis histopathology
The AHF pancreatitis rats gain less body weight per week
compared to control rats fed standard rodent chow. The
final weight gain plateau in AHF fed rats was significantly
less than that of control rats (data not shown), but was
within the 20% safety limit of the American Veterinary
Medical Association Guidelines on Euthanasia (2013) and
local institutional Animal Care and Use Committee (IACUC)
guidelines. In patients, chronic pancreatitis can be accom-
panied by weight loss due to symptoms (abdominal pain,
nausea and anorexia), decreased pancreatic enzymes and
nutrient absorption, and alcoholic dietary deficiencies [25].
Chronic pancreatitis pathology with fibrosis and
vacuolization in AHF fed rats
Pancreas tissues were taken from both normal chow
control and AHF pancreatitis rats in week 12 at the end
of the experiment. Pancreas from normal chow fed rats
had normal architecture with evenly distributed acini
and islets of Langerhans (Figures 1A; 2A). Histological
assessment of pancreas from rat with AHF pancreatitis
revealed global gland degeneration (acinar and islet
cell atrophy), abundant vacuolization (fat deposition)
(Figure 1B), as well as invasive periductal, interlobular,
and intralobular fibrosis (Figure 2B). Inflammatory cells
were not detected in the pancreas tissue sections.
The total overall histology severity score (HSS) for the
pancreas of the AHF fed group was 5±0 (median = 5)
(n = 6) for the head (duodenal lobe) and 6.33±0.33
(median = 6) (n = 6) for the tail (splenic lobe) (Figure 1D).
This was significantly different compared to an HSS of 0
(median = 0) for the normal chow control group (n = 6,
p < 0.05, One-way ANOVA, Kruskal-Wallis).
Quantitative analysis of the percentage of the total
pancreatic area positive for collagen staining (reflecting
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fibrosis) demonstrated a significant increase of >17% in
AHF fed rats, compared to <7% in the control group
(Figure 2D). The total fibrosis in the pancreas head was
17.29±1.9% and in the tail was 17.20±1.2% from the AHF
pancreatitis rats. This was a statistically significant
increase compared to the controls (n = 6, p < 0.01and
p < 0.001, respectively, Student’s t-test).
These data show that the AHF induced chronic
pancreatitis rat model featured a globally disrupted
pancreatic pathology; including acinar and islet cell
atrophy, progressive accumulation of lipid droplets in
acinar cells (vacuolization), and periductal, interlobular and
intralobular fibrosis. Pancreatic infiltration by immuno-
competent inflammatory cells was not detected in any of
the tissue sections. These chronic morphological changes
in rats with AHF chronic pancreatitis are consistent with
pathological changes described in clinical samples from
patients with alcoholic pancreatitis [26,27].
LY3038404 HCl preserved pancreatic architecture in rats
with AHF pancreatitis
LY3038404 HCl effectively blocked the widespread
progress of pancreatic tissue degeneration described above
for chronic AHF pancreatitis rats (Figure 1C and D). The
HSS was 2±0 (median = 2) for the head and 2.33±0.33
(median = 2) for the tail in the AHF + LY3038404 HCl
treated group. This was not different from the normal
chow control group and was significantly improved com-
pared to the HSS of 5 – 6 range in AHF pancreatitis rats
without drug treatment group (p < 0.05, One-way ANOVA,
Kruskal-Wallis).
The total collagen staining area was significantly
decreased to 7.4±0.68% in the head and 5.98±0.33% in the
tail of the AHF + LY3038404 HCl treated group compared
to the untreated AHF rats with pancreatitis (Figure 2C
and D) (p < 0.01 and p < 0.001, One-way ANOVA,
Tukey's Multiple Comparison test). This was within range
of the percentage obtained from the control rats. Thus,
the decreased percentage of the total pancreatic area
staining positively for collagen and the overall pancreatic
architecture demonstrated improvement in the LY3038404
HCl treated rats.
Increased Ki67 cell proliferation protein expression in
injured pancreas
There were few basal Ki67-positive cells observed in
pancreas of normal chow fed control rat (2.37 ± 0.7/mm2)
(Figure 3A). The cell proliferation protein Ki67 was evident
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Figure 1 AHF diet induced chronic pancreatitis pathology and protection by LY3038404 HCl. Representative bright field images of
pancreatic paraffin sections stained with H & E. A. Normal chow fed rats had normal pancreatic architecture with evenly distributed acini and
islets of Langerhans. B. Rats with AHF diet chronic pancreatitis had abnormal pancreatic tissue architecture including global degeneration (with
blurred cell borders) and multiple vacuolization sites due to fat deposition. C. LY3038404 HCl treated rats with AHF pancreatitis showed
improvement of tissue damage. D. The histogram shows the histological severity rating scores (HHS) of different treatment groups. The score is a
total of the different parameters for each animal averaged within each group, expressed as a median (One-way ANOVA, Kruskal-Wallis, *p < 0.05).
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in the AHF fed animals mainly expressed in the nuclei of
acinar cells and in some periductal epithelial cells
(Figure 3B). The increased number of Ki67 positive cells in
the injured pancreas of AHF fed rats was statistically signifi-
cant compared to control chow fed rats (9.56 ± 1.6/mm2)
(Figure 3D) (p < 0.01, One-way ANOVA, Tukey's Multiple
Comparison test, n = 6/group). This was consistent with
other reports of tissue injury and repair activities in acute as
well as in chronic pancreatitis following long term insult
to the pancreas [28-30]. The increased presence of the pro-
liferation biomarker Ki67 is suggestive of cellular events
that favor progression to tumor development [31].
LY3038404 HCl diminishes Ki67 indicated cell proliferation
Pancreatic immunostaining for Ki67 positive nuclei
revealed a similar mean number of positive nuclei
comparing LY3038404 HCl treated pancreatic group
with the normal control rats (Figure 3A, C and D)
(3.34 ± 0.27/mm2 vs 2.37 ± 0.74/mm2; p > 0.01, One-way
ANOVA, Tukey's Comparison test).
Thus, orally administered LY3038404 HCl exerted
protective effects in the pancreas, significantly reducing
Ki67 upregulation and AHF induced tissue damage. The
CB2 agonist treatment given in week 6 after the start of
AHF diet significantly protected the pancreatic tissues
from severe degeneration, vacuole formation and fibrosis.
LY3038404 HCl’s tissue protective effect is most
likely related to key roles of CB2 receptor activators
as antioxidants and inhibitors of cell proliferation
shown by others [32]. This tissue protective effect is
supported by the preponderance of studies to date indicat-
ing that the CB2 cannabinoid receptor is linked to cyto-
chrome P450 mono-oxygenases [33] and is a modulator of
the majority of immune functional responses [12,14,34].
Michler et al. [24] demonstrated the importance of
CB2 activation in protective modulation involving
MAPK p38 and MK2 dependent pathways in an acute
pancreatitis model. A similar study also demonstrated that
local peripheral CB2 receptor activation inhibits inflam-
mation and inflammatory hyperalgesia [35]. AM1241, a
selective agonist of CB2, fully reversed carrageenan-
induced inflammatory heat hyperalgesia when injected
directly into an inflamed paw. In contrast, AM1241
injected into the contralateral paw had no effect, demon-
strating CB2 receptor activator has a local peripheral
effect.
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Figure 2 Chronic pancreatitis pathology with fibrosis and LY3038404 HCl effectively reduced pancreatic tissue fibrosis. Representative
bright field images of Sirius red stained pancreatic sections. A. Normal chow control group had little fibrosis. B. AHF pancreatitis group rats had
an invasive fibrous network around the acini, blood vessels, and ducts. C. LY3038404 HCl treated rats with AHF pancreatitis showed an
improvement with much less tissue fibrosis. D. The histogram shows the statistically significant increase in percent fibrosis relative to total tissue
area in AHF fed rats with chronic pancreatitis compared to the controls (n = 6/group, **p < 0.01 and ***p < 0.001). LY3038404 HCl treatment
effectively protected rats with AHF pancreatitis from severe pancreatic tissue damage (n = 6/group, ##p < 0.01 and ###p < 0.001).
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Pain related behaviors induced in rats with AHF diet
chronic pancreatitis
Secondary hindpaw mechanical allodynia
The baseline for the 50% paw withdrawal threshold to
mechanical stimulation (von Frey fiber test) was initially
similar for both the control chow fed and the AHF fed
rat groups, i.e. 18.57±0.09 g for both feet. The AHF
fed rats developed hindpaw mechanical hypersensitivity
three weeks after the start of the AHF diet. The mechanical
threshold was progressively decreased from week 3, reached
maximum hypersensitivity at week 5, and remained low
throughout the subsequent weeks with continuous feeding
of the AFH diet. The paw withdrawal threshold was
decreased to 4.21±0.39 g bilaterally, a significant difference
compared to that of the control chow fed group
(17.10±0.09 g) (p < 0.001, Two-way ANOVA, Bonferroni
post-test) (Figure 4A).
Secondary abdominal heat hyperalgesia
The baseline abdominal withdrawal latencies (ABWL) of
the control chow and AHF fed groups were similar
(control chow (n = 6) 13.6 ±1.19 s vs. AHF (n = 12)
13.39±1.4 s). The secondary heat hyperalgesia on the
abdominal skin developed in the fourth week in AHF
diet fed rats. The ABWL decreased from baseline
13.39±1.4 s to 8.77±0.28 s, compared to the unchanged
ABWL in the control chow fed group (13.41±1.2 s)
(p < 0.001, Two-way ANOVA, Bonferroni post-test).
The ABWL persisted at this low level for the remainder of
the experimental time course (Figure 4B).
Increased nocifensive responses to noxious 44°C stimulation
Nocifensive responses to the modified 44°C hotplate test
were recorded for all groups. To normalize the skin
temperature of the feet at testing, all rats were first
placed on a 38°C hotplate for 10 min, then immediately
transferred onto the 44°C hotplate. The nocifensive
responses recorded were as follows (1 minute/bin):
hindpaw licking/guarding events; the first response
latency (hind-paw withdrawal latency) and rearing events.
The hindpaw withdrawal response latency to the noxious
heat stimuli (44°C) in control rats was 260.53±27.2 s. The
accumulated hindpaw lick/guarding events occurred an
average of 8.33±1.9/10 min. In contrast, the first hindpaw
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Figure 3 Increased Ki67 immunoreactivity in pancreatic tissue and LY3038404 HCl effectively inhibited the expression of Ki67. Pancreas
tissue sections are shown. A. Control pancreas tissue has low basal Ki67 expression in the acinar cell nuclei. B. Numerous Ki67 positive cell nuclei
are evident in the pancreas of rat with AHF pancreatitis. C. Chronic treatment with LY3038404 HCl effectively blocked Ki67 expression. D. The
histogram shows the cell count per mm2 pancreas tissue section. There is a statistically significant difference in Ki67 staining between normal
chow fed animals and animals with AHF pancreatitis (One-way ANOVA, Tukey's Multiple Comparison test, n = 6/group, **p < 0.01). LY3038404
HCl treatment effectively reduced Ki67 expression in rats with AHF pancreatitis (n = 6/group, ##p < 0.01). Scale bar = 50 μm.
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withdrawal latency in rats with AHF pancreatitis started
as early as 208.6±30.2 s. The average of accumulated
hindpaw licking/guarding events was 17.2±3/10 min.
The event/time curve clearly showed a significant
left-ward shift compared to that of the control chow
group (p < 0.05, Two-way ANOVA, Bonferroni post-test,
n = 6/group) (Figure 4C). The rearing or wall leaning
posture was recorded during the 10-minute 44°C
hotplate assay. Rats with AHF pancreatitis displayed
more rearing events (25 ± 1.3/10 min) than control chow
fed rats (18.33 ± 0.6/10 min) (Figure 4D; p < 0.05,
Student’s t-test). This assay documented the development
of secondary heat hyperalgesia and increased escape
responses in rats with AHF pancreatitis.
Thus, in this study, rats with AHF induced chronic
pancreatitis demonstrated progressively increasing visceral
pain-like behaviors, as well as secondary hypersensitivity.
Secondary hypersensitivity was indicated by decreased
mechanical threshold (secondary mechanical allodynia) and
shortened response latency to noxious heat stimuli
(secondary heat hyperalgesia), tested in two somatic
referred pain regions (paw and abdomen). Rats with
chronic pancreatitis displayed more complex pain-like
behaviors and escape activity in the 44°C hotplate assay.
These behaviors included frequent hindpaw lifting and
licking (secondary heat hyperalgesia) and increased rearing
events (attempted escape) in response to the noxious heat
stimuli.
LY3038404 HCl effectively attenuated pain related
behaviors
Long term oral feeding of LY3038404 HCl effectively
attenuated pain related behaviors in rats with AHF
pancreatitis.
Paw Withdrawal Threshold (PWT)
LY3038404 HCl was given twice a day for 7 days
(10 mg/kg, p.o.). Pain related behavioral testing (PWT
and ABWL) was performed one hour after the second
dosing of the day and similar testing was repeated
every day for the entire drug treatment course (7 days).
Progressive elevations of paw mechanical thresholds were
noted in the AHF pancreatitis rats after three days of
receiving LY3038404 HCl treatment. The 50% PWT
(in grams force) on both feet was increased to 14.11±2.3 g
in the group with drug treatment on the seventh day. This
was a statistically significant increase from the non-
treatment AHF pancreatitis group (4.69±0.39 g) (p < 0.001,
n = 6/group, Two-way ANOVA, Bonferroni post-test)
(Figure 5A).
Abdominal Withdrawal Latency (ABWL)
ABWL was assessed immediately after the PWT testing
each day. The abdominal withdrawal latency was progres-
sively prolonged 3 days after LY3038404 HCl treatment.
The average ABWL before drug treatment was 7.05±0.5 s
and increased to 11.041±0.59 s at the end of the 7 day drug
treatment. There was a statistically significant difference in
the ABWL of AHF pancreatitis rats between the LY3038404
HCl treatment group (11.041 ± 0.59 s) and the rats without
drug treatment (7.18±0.59 s) (p < 0.05, n = 6/group,
Two-way ANOVA, Bonferroni post-test) (Figure 5B).
Nocifensive responses to noxious heat stimuli
(44°C hotplate)
On treatment day 8, LY3038404 HCl significantly
prolonged the first response latency (421±90 s) and
reduced the cumulative amount of hind-paw licking
or guarding reflex events (4.66±2.4/10 min) compared to
AHF pancreatitis rats without drug treatment (259.6±60 s;
7.66±2.3/10 min). The event/time curve of the drug
treatment group showed a right-ward shift compared
to the nondrug treatment group (Figure 5C).
Rats with AHF pancreatitis display decreased anxiety-like
behaviors in two compartment light/dark box testing
It is known that Fischer 344 strain rats innately exhibit
greater anxiety and fear-motivated behaviors (e.g. relatively
low open field exploratory behaviors, social contact, and
low running wheel activity) compared to many other rat
strains [36,37]. We used the light–dark box test to assess
anxiety-like phenotypes. Rats chronically fed the AHF diet
(See figure on previous page.)
Figure 4 Rats with AHF chronic pancreatitis developed secondary hypersensitivity. A. Hindpaw Mechanical Allodynia. The baseline for
the 50% paw withdrawal threshold to mechanical stimulation (von Frey fiber) was similar in control chow fed rats and the AHF fed group. The
mechanical threshold was progressively decreased in the AHF fed group starting from week 3 and reaching maximal hypersensitivity at week 5.
The paw mechanical allodynia remained through the entire experiment time course (Two-way ANOVA, Bonferroni post-test,***p < 0.001).
B. Abdominal Secondary Heat Hyperalgesia. The baseline for abdominal withdrawal latency (ABWL) was similar between control chow and AHF
fed groups. Secondary heat hyperalgesia developed on the abdominal skin area in the fourth week of AHF feeding. The abdominal withdrawal
latency (ABWL) baseline of 13.39±1.4 s was decreased to 8.77±0.28 s and remained at this level throughout the experimental time course. This was a
statistically significant difference compared to the control chow fed group (Two-way ANOVA, Bonferroni post-test, ***p < 0.001). C. and D. 44°C
Hotplate Hypersensitivity Assay. C. The nocifensive responses were recorded for 10 min (1 minute per bin). The event/time curve in rats with
pancreatitis showed a statistically significant left-ward shift compared to that of the normal chow fed control group (Two-way ANOVA, Bonferroni
post-test, n = 6/group, *p < 0.05). D. The rearing events on the hotplate were significantly increased for rats with AHF pancreatitis compared to
normal chow fed rats (t-test, *p < 0.05).
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and control rats fed normal chow were placed into the
light–dark box and monitored for 10 min.
During the assessment in the test apparatus, the
control chow fed rats preferred the dark. They remained
in the dark chamber for 70% of the total testing time as
previously reported by others [38]. However, AHF pan-
creatitis rats displayed 50/50 light/dark occupancy and
had more exploratory activity transitions between the light
and dark chambers. The AHF fed rats with pancreatitis
spent a significantly increased amount of time in the light
compartment compared to the control rats fed chow
(300.77±36.45 s vs. 148.97±15.7 s) (p < 0.05, Student’s
t-test) (Figure 6A). In rats with AHF pancreatitis, the
greater number of accompanying transitions between
the light and dark compartments (6 ± 0.66/10 min)
was also statistically significant compared to control chow
fed rats (4±0.57/10 min) (p < 0.05, Two-tailed t-test)
(Figure 6B).
This behavior in the AHF rats with pancreatitis may
be due to masking of any test related anxiety-like
behaviors as a result of the long term ethanol consumption
[38-42]. McCool et al. [42] showed that chronic ethanol
exposure increased the functional expression of GABAA
receptors in the neurons of basolateral amygdala which is
included in the brain alcohol reward system. The facilita-
tion of GABAA receptors during chronic ethanol exposure
might help explain the maintenance of ethanol’s anti-
anxiety effects during chronic ethanol exposure.
LY3038404 HCl did not affect higher brain functions
Long term oral feeding of LY3038404 HCl had little or
no effect on light dark preference (Figure 6 C&D) and
open field exploratory (Figure 7) behaviors in rats with
AHF pancreatitis.
Two chamber dark/light box testing
During a 10 min time course exposure to the two chamber
light/dark preference test apparatus, rats fed the control
chow allocated the majority of their time to the dark
chamber with only 164.03±11.23 s occupancy in the light
(See figure on previous page.)
Figure 5 LY3038404 HCl attenuated evoked pain related behaviors. LY3038404 HCl (10 mg/kg, oral, twice a day, 7 days), effectively
attenuated pain related behaviors. A. Secondary paw mechanical allodynia was reduced (AHF vs. AHF + LY3038404 HCl, n = 6/group, Two-way
ANOVA, Bonferroni post-test, *p < 0.05; **p < 0.01; ***p < 0.001). B. Secondary abdominal heat hyperalgesia was reduced (AHF vs. AHF + LY3038404 HCl,
Two-way ANOVA, Bonferroni post-test, n = 6/group *p < 0.05, **p < 0.01, ***p < 0.001). C. LY3038404 HCl (10 mg/kg, twice daily, 8 days) reduced
hypersensitivity to noxious 44°C hindpaw stimulation (10 min). LY3038404 HCl prolonged the first response latency and reduced the cumulative
amount of hind-paw lick or guard reflex events. Compared to rats without drug treatment, the event and time curve of drug treatment group showed
a right-ward shift.
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Figure 6 LY3038404 HCl did not affect light/dark box preference. A. Rats with AHF pancreatitis spent more time in the light compartment
(300.77±36.45 s) than did rats fed regular chow (148.97±15.7 s) (t-test, *p < 0.05). B. The number of transitions between the light and dark
compartments was increased in rats with AHF pancreatitis (6±0.66/10 min) compared to normal chow controls (4±0.57/10 min, t-test, *p < 0.05).
C. LY3038404 HCl (10 mg/kg, oral feeding, twice daily, for 9 days) did not affect the light/dark preference behaviors of AHF pancreatitis rats. The
time spent in the light compartment for rats with AHF pancreatitis without drug treatment (287.1±6 s) was similar to that of the drug treatment
group (275.4±22.3 s) (One-way ANOVA, *p < 0.05). D. The number of transitions between the light and dark compartments for rats with AHF pancreatitis
(7.33±0.85/10 min) was significantly greater than control chow fed rats (3.2 ± 0.6/10 min, *p < 0.05), but there was no effect with drug treatment
(7.67±0.61/10 min) (Chow vs. AHF, AHF vs. AHF + LY3038404 HCl, One-way ANOVA, Tukey's Multiple Comparison test, n = 6/group, p > 0.05).
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chamber (Figure 6C & D) (p < 0.05, One-way ANOVA,
Tukey's Multiple Comparison test). Rats with AHF
pancreatitis showed reduced anxiety-like behaviors
indicated by almost 50/50 occupancy of both the light
and the dark chambers, with a light chamber preference
of 287.1±6.09 s occupancy. AHF pancreatitis rats had
an increased number of light/dark chamber transi-
tions (7.67±0.61/10 min) compared to control chow
fed rats (3.2±0.6/10 min).
The LY3038404 HCl (10 mg/kg, twice daily, for 9 days)
treatment had no effect in AHF pancreatitis rats either
for light/dark preference or the number of transitions
between chambers, i. e. time spent in light: 275.4±22.3 s,
the number of transition: 7.33±0.85/10 min (p > 0.05,
AHF vs. AHF + LY3038404 HCl, One-way ANOVA)
(n = 6/group) (Figure 6C & D).
Open field exploratory activities
An open field test was performed after two additional
consecutive days of LY3038404 HCl treatment, to assess
CB2 agonist effects on the six exploratory activities and
anxiety-like behavioral measures in the rats (Figure 7).
LY3038404 HCl had no significant effect on any of these
parameters used as comparative assessments of higher
order exploratory behavior and motor function. The
following six parameters reflecting animal exploratory
and motor activities were assessed: rearing events and
rearing duration; total activities (by beams broken),
total distance traveled and total times while active
and at rest (n = 6). No significant difference in behaviors
of the AHF pancreatitis group and the chow fed
group (p > 0.05).
Correlation analysis of histopathology and pain related
behaviors
Further analysis of the correlation coefficient (Microsoft
Excel) between severity of pancreatic tissue damage
(HSS and percent tissue fibrosis) and pain related nocifen-
sive responses (mechanical hind paw withdrawal threshold
and heat abdominal withdrawal latency) revealed a strong
negative correlation for these two assessments. Pancreatic
tissue damage severity was correlated with pain related
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Figure 7 LY3038404 HCl did not affect rat exploratory activities. LY3038404 HCl (10 mg/kg, twice daily, 9 days) did not affect any
parameters of the rat open field exploratory behavioral activities (rearing events, rearing duration, total activities, distance traveled, total active
time and total resting time (n = 6/group). There were no significant differences in the responses with or without drug treatment (p > 0.05).
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behavioral measures for all three rat groups, control chow
fed, AHF fed, and AHF + LY3038404 HCl ) (Figure 8). The
AHF pancreatitis animals with higher HHS had lower
mechanical threshold (Figure 8A) and a shortened heat
withdrawal latency (Figure 8B). These results were also
reflected when assessing collagen staining. Animals
with a higher percentage of fibrosis had lower mechanical
thresholds (Figure 8C) and shortened heat withdrawal
latencies (Figure 8D). These correlative analyses are
supportive of LY3038404 HCl as a protective treat-
ment for reducing severe pancreatic tissue damage
and hypersensitivity.
Based on the histopathology and behavioral test correla-
tions, it is suggested that suppression of referred mechan-
ical allodynia and heat hyperalgesia by LY3038404 HCl may
be the result of the combined effects of reduced pancreatic
pathology and inhibition of nociceptive peripheral nerve
activity due to the long term CB2 receptor activation.
In summary, the LY3038404 HCl attenuated evoked
mechanical and heat pain related behaviors, but had no
effect on anxiety-like behavior. The LY3038404 HCl
increased paw withdrawal threshold (PWT), prolonged
abdominal withdrawal latency (ABWL), and decreased
nocifensive responses to noxious 44°C hotplate stimuli.
These findings are consistent with a previous study in
which HU210, a synthetic agonist at CB1 and CB2, abol-
ished abdominal pain associated with acute pancreatitis,
reduced inflammation, and decreased tissue pathology in
mice without producing adverse central effects [23].
A recent study demonstrated that activation of CB2
receptor inhibits bladder inflammation and associated
referred mechanical hyperalgesia in a mouse cystitis
model [43]. Orally administered PF-03550096 (10 mg/kg), a
potent CB2 agonist, also inhibited the 2,4,6-trinitrobenzene
sulfonic acid (TNBS)-induced decrease in pain threshold in
a rat model of visceral (colonic) hypersensitivity [44].
These reports and the data presented here indicate
that cannabinoids are generally beneficial in visceral
inflammatory disorders and visceral pain.
Our data revealed that LY3038404 HCl altered neither a
light/dark preference behavior nor open field exploratory
activity in the AHF pancreatitis rats. This indicates
LY3038404 HCl did not affect higher brain mediated
behaviors and was not associated with central side effects
reported for CB1 agonists in previous studies [12-15].
These findings support beneficial peripheral CB2 receptor
signaling mechanisms of action for LY3038404 HCl.
Activation of CB2 receptors located on peripheral terminals
of nociceptors or local cells could diminish nociceptor
excitability and thus block pain signaling [10,21].
Conclusion
The major finding of the present study is that LY3038404
HCl, a potent CB2 receptor agonist, possesses tissue pro-
tective and analgesic properties. No effects on higher brain
functions were observed including the diminished fear
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Figure 8 Correlation analysis among pain behaviors and tissue pathology. Pancreatic tissue damage and pain related behavioral measures
were correlated in the three groups of rats (control chow fed rat, rat with AHF pancreatitis and rat with AHF pancreatitis + LY3038404 HCl).
A. Animals with higher pathology scores (HSS) had lower mechanical thresholds. B. Animals with higher pathology scores (HSS) had shortened
abdominal heat withdrawal latencies. C. Animals with a higher percentage of fibrosis had lower mechanical thresholds. D. Animals with a higher
percentage of fibrosis had shortened abdominal heat withdrawal latencies.
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responses induced by the alcohol diet. Thus, activation of
CB2 receptors is suggested as a potential therapeutic target
for pancreas protection and pain management.
Methods
The studies were performed in accordance with the
Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health and were
approved by the University of Kentucky Institutional
Animal Care and Use Committee.
Experimental design
These studies were performed in order to evaluate the
therapeutic efficiency of a novel CB2 receptor agonist
LY3038404 HCl in the AHF chronic pancreatitis rat
model. After the nocifensive behaviors were established,
i.e. six weeks after the start of the alcohol/high fat liquid
diet feeding, the LY3038404 HCl was given twice a day
for 7 days (10 mg/kg, p.o.). The pain related behavioral
tests were performed one hour after the second drug
dosing each day. Higher order preference tests were
performed on two additional days of treatment. At
the conclusion of the study, animal pancreatic tissues were
harvested to evaluate the severity of the pancreatitis. The
therapeutic efficiencies of LY3038404 HCl were evaluated
by analyzing 1) pancreatic tissue HSS and fibrosis for
tissue protection; 2) evoked, place preference, and open
field behavioral data for determination of nociceptive
control and side effects.
Induction of chronic pancreatitis
Male Fischer 344 rats weighing between 240 – 250 g
(Harlan Sprague–Dawley, Indiana) were used for this
study. Rats were randomly divided into two groups:
alcohol/high fat liquid diet (AHF) fed - (n = 12) and
control chow fed- group (n = 6). Animals were single
caged and kept in a temperature constant (23° ± 2°C)
room on a 12/12 hour reversed dark–light cycle.
Chronic pancreatitis was induced in animals fed an
alcohol/high fat liquid diet (AHF) made from micro-
stabilized rodent alcohol liquid diet mix (LD 101A;
Test-Diet, Richmond, IN), composed of 3.9% fat from
corn and safflower oil, 30.3% protein, 5% fiber, vitamins
and minerals added as a dry powder to water and alcohol
(w/v, 95% ethyl alcohol). The dose of alcohol was progres-
sively increased from 4% to 6% as follows: 4% alcohol for
the first week, 5% for second week, and 6% for the third
to eighth week. Lard (8 g/per rat/per day) was added start-
ing from the 4% alcohol week. Rats were allowed free ac-
cess to water. Each rat consumed between 50–70 grams of
liquid diet with alcohol per day for 12 weeks. Animals also
received a daily lard supplement (8 g/day/per rat) bringing
the total fat content of their diet to ~20% total daily
dietary fat consumption. Control group was fed standard
rodent chow (Teklab 8626, Harlan, Indiana) and they had
access to food and water ad libitum. Animals were
observed closely and no evidence of alcohol intoxication
(no ataxia or lethargy) was noted. Body weight was moni-
tored weekly and food consumption was monitored daily.
Drug administration
LY3038404 HCl and dosages were provided by Eli Lilly
and Company, Indianapolis IN. LY3038404 HCl powder
was freshly mixed with control rat chow powder and
drinking water to form a small drug pellet (≈1 g/each) one
day before use. The small pellets were dried in a 50°C-oven
for 2 hours.
The LY3038404 HCl treatment started after the 6th week
when pain related behavior testing detected a maximum
hypersensitivity in the AHF fed animals. Rats were fed
LY3038404 HCl (10 mg/kg) orally twice a day for 9 con-
secutive days. On the testing day one pellet was given at
8:30 - 9 am, and one at 12 - 1 pm. The evoked mechanical
and heat tests were performed on Days 1–7, one hour after
the second dosing of the day. Place preference and open
field tests were performed on Days 8 and 9, respectively.
Histopathological assessment of pancreatitis
At the end of study, rats were anesthetized with pento-
barbital (100 mg/kg, i.p.) and perfused transcardially
with warm heparinized saline followed by 4% ice-cold
paraformaldehyde in 0.1 M phosphate buffer solution
(pH 7.4). The pancreas was post-fixed in the buffered
paraformaldehyde for 48 hours, carefully dissected
into 2 parts: duodenal (pancreatic head) and splenic
lobes (pancreatic tail) were put into 70% alcohol.
After dehydration through graded ethanol (95, 100%),
the pancreas was embedded in paraffin. Pancreatic tissue
sections were cut at 5 μm thickness, mounted onto gelatin
coated glass slides (Super Frost Plus, VWR, Radnor, PA),
and stored at room temperature for histological staining.
Analysis was performed blindly on serial sections from
each rat.
Hematoxylin and Eosin (H&E) staining
Slides were de-paraffinized with Citrosolv (Fisher, Pittsburgh,
PA), hydrated with graded ethanol, rinsed in tap water,
immersed in 0.1% hematoxylin (Fisher) for 1–3 min, washed
in tap water for 1 min, dehydrated through in graded ethanol
(50%, 70%), immersed in 0.1% eosin (Fisher) for 1 min, and
then dehydrated in 90% ethanol. Finally, sections were
dehydrated in 100% ethanol and coverslipped with
Permount (Fisher, Pittsburgh, PA).
Sirius Red staining for collagen
De-waxed and hydrated paraffin sections were stained
with haematoxylin for 8 minutes and then washed for
10 minutes in running tap water. Sections were stained
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in picro-sirius red for one hour. After two washes in
acidified water, sections were dehydrated in three changes
of 100% ethanol, cleared in Citrosolv (Fisher, Pittsburgh,
PA), and coverslipped with toluene based mounting
medium (Fisher, Pittsburgh, PA).
Immunostaining for Ki67 cell proliferation biomarker
Pancreatic tissue proliferation in response to injury was
monitored by immunostaining of the nuclear proliferation
marker Ki67. Pancreatic paraffin tissue sections were
exposed to antigen-retrieval in boiling Tris-EDTA Buffer
(10 mM Tris Base, 1 mM EDTA Solution, 0.05%
Tween 20, pH 9.0), followed by antibody incubation
and detection using the ABC-Vectastain system with
the Vector DAB substrate kit (Vector Laboratories,
INC, Burlingame, CA). Sections were counterstained
with Eosin. Primary antibody was rabbit anti-Ki67 (Abcam,
Cambridge, UK). Quantification was performed by counting
Ki67 positive cells in an entire tissue section using a
20× objective. The image of the whole tissue section
was captured with a digital camera (Canon, PowerShot,
ELPH 300HS). The total area (mm2) of the entire tissue
sections was measured with the Image J program (v1.46r;
NIH), and the number of Ki67 positive cells per mm2 area
was determined.
Pancreas Histological Severity Scoring (HSS)
Hematoxylin-eosin (H&E) staining was performed on 5 μm
paraffin embedded pancreatic sections. Severity of
pancreatic tissue damage was graded by a semi-quantitative
scoring system (HSS). Within pancreatic sections, areas of
abnormal pancreatic tissue architecture were graded: global
glandular degeneration (acini and islets), vacuolization
(fat deposition), acinar and islet cell atrophy including
focal atrophy, area atrophy; and fibrosis: periductal,
interlobular and intralobular fibrosis. These parameters
were graded as follows: 0, absent; 1, minimal (<10%); 2,
moderate (30 - 50%); and 3, major (>50 - 70%) percentage
of the entire pancreatic section examined, as described by
others previously [25-27,45,46]. Sections were observed and
graded by two examiners blinded to animal treatment. A
total score was calculated for both pancreatic head and tail.
Quantitative analysis of pancreas fibrosis with image J
The fibrous collagen in 5 μm-thick pancreas sections
was stained with Sirius red. With this type of histological
staining, the fibrous collagen deposition was stained red.
Bright-field, polarized, TIFF images from the pancreas head
and tail were acquired from consecutive non-overlapping
fields using a Nikon E1000 microscope equipped with a
Nikon DXM1200F digital camera and ACT-1 Program
(Nikon Instruments, Inc., Melville, NY). Five images of each
section were taken with 20× magnification at full resolution
with a single image dimension setting of 3600 × 2880 pixels.
The percentage of fibrotic tissue area was compared to the
total area of tissue within an image. Mean values
were obtained from 5 images of pancreas sections for
each animal for comparison of groups.
Quantitative analysis of pancreatic fibrosis was performed
using the Image J program (v1.46r; NIH) with the color
thresholding plug-in. The threshold is set specifically for
the Sirius red stained component (fibrosis). After setting
the scale, the percentage of fibrosis was calculated by
determining the tissue areas occupied by collagen fibers
versus the total pancreas tissue areas, excluding the lumen
(i.e., empty spaces) [47,48] (Reinking L, 2007 Image J Basics
http://rsbweb.nih.gov/ij/docs/pdfs/ImageJ.pdf; Examples of
Image Analysis Using ImageJ http://rsb.info.nih.gov/ij/docs/
pdfs/examples.pdf). The fibrosis % (of total tissue) = (area
of fibrosis /area of total tissue) x100, i.e. = (area of entire
image- non threshold area) / (area of entire image- area of
empty space) × 100.
Pain related behavioral assessments
Weekly behavioral testing was performed during the ani-
mal’s dark cycle active period (i.e. 0900 h – 1500 h). Investi-
gators performing the behavioral studies were blinded to
animal treatment.
Assessment of hindpaw secondary mechanical allodynia
Secondary mechanical allodynia on the hindpaws was
assessed by measuring the mechanical withdrawal
threshold using von Frey filaments with the “up - down”
method described by Chaplan et al. [49]. Animals were
placed on a raised wire mesh table (76 ×38 cm), under a
clear plastic ventilated rat restrainer (18 ×13 ×15 cm)
for a 30 min acclimatization period. The mechanical
withdrawal threshold testing was done on the plantar
surface of both hindpaws using a set 8 of von Frey
monofilaments. The von Frey filaments were applied
perpendicularly to the plantar surface with sufficient
force to bend the monofilament slightly and held for
about 5 seconds. A positive response was defined as an
abrupt withdrawal (flick response) of the foot during
stimulation or immediately after the removal of stimulus.
Whenever there was a negative or positive response, the
next stronger or weaker filament was applied, respectively.
The pattern of positive and negative responses was
converted into a 50% threshold value (in grams) using
a curve-fitting algorithm [50]. The 50% decreased
paw withdrawal threshold (PWT) indicated secondary
mechanical allodynia.
Assessment of abdominal secondary heat hyperalgesia
Nocifensive responses to heat stimuli were tested by
measuring the abdomen withdrawal latency with the
modified Hargreaves test [51]. The radiant heat source
was shone onto the abdominal skin of the reclining rats.
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Rats’ abdominal skin was shaved one day before the test
each week. Rats were placed in separate clear plastic
ventilated restrainers (18 ×13 ×15 cm) on a glass-top
table (approximately 2 mm thick glass) and allowed to
acclimate to their new environment for 30 min before
testing. A high-intensity light beam was applied to the
shaved abdominal skin surface through the glass and
the latency of reflexive withdrawal responses timed
(seconds). The cutoff time for abdominal withdrawal
latency was set at 40 s to avoid any damage to the
skin. A withdrawal event to radiant heat was defined
as a weight shifting (either abdominal musculature
contraction or lifting of the abdomen through postural
adjustment) accompanied by head turning toward the
stimuli and licking of the abdominal area. The abdomen
withdrawal latency was tested in 3 trials for averages. The
5-min intervals between trials and a cooling fan under the
table assured the temperature of the glass surface returned
to room temperature (22 - 24°C) prior to the next trial.
Shortened abdomen withdrawal latency values indicated a
secondary heat hyperalgesia.
Modified 44°C hotplate test
Because C-fiber nociceptors are active under sustained,
low-intensity heat stimulation, the modified hotplate test
assessed responses to moderately noxious stimuli [52,53].
In this study, two temperature controlled hotplates were
topped with vented Plexiglas enclosures (26 cm × 26 cm ×
28 cm) (Columbus Instruments, OH). One hotplate
temperature was set at 38°C for pre-warming to normalize
all animal paw temperatures, and the other one was set at
44°C. After a 30 min acclimation to the environment, rats
were placed on the 38°C warm-up plate for 10 min. Then
the rats were placed on the 44°C test plate for a 10 min test
period. The latency to the first hindlimmb withdrawal
response, the duration, and the frequency of hindlimb
withdrawal events during heat stimulation were recorded.
Event duration with hindpaws withdrawn from the plate
began when the limb was lifted and finished when the
limb made contact with the plate again. The events were
plotted against time at 1 min intervals and a leftward shift
of the event/time curve was an index of heat hyperalgesia.
Erect leaning posture with forelegs against the wall of the
enclosure (rearing event) was recorded. Rearing events
were considered a noxious-evoked escape response during
the hotplate test [54,55].
Exploratory activity testing
Open field exploratory activity of the animals was
monitored using the automated Flexfield Animal Activity
System (San Diego Instruments, San Diego, CA) with
Photobeam Activity System software (PAS) coupled to a HP
computer (Hewlett Packard, Palo Alto, CA). The activity
enclosure included a transparent Plexiglas chamber
(40 × 40 ×40 cm) equipped with infrared photobeam
sensors, 16 beams on each axis ( X and Y, total 32),
arranged 4 cm above the chamber floor. Obstruction
of these photobeams constitutes movements in the x and
y planes. Another set of 16 beams is located 12 cm above
the chamber floor to record movements in the z-plane
(rearing events and duration). Data were collected for
45 minutes in nine 5-minute intervals.
The experiment was carried out in an isolated, tem-
perature controlled (21 - 22°C) room, with consistent
background white noise. When the tests started, the
observer exits the room leaving the subjects undisturbed.
Animals were tested at the same time of the day (from 9
am to 3 pm). To avoid acclimation of animals to the
environment, repeat testing of the same animal occurred
at least 24 h after the last test [56]. Six main parameters
were measured in the nine 5 min intervals: rearing events
and rearing duration; total activities, i.e., number of
photobeams broken (included the number of different
zone entries and stationary fine movement, e.g., grooming)
and distance traveled; active time and resting time. Resting
time is defined as a period when the animal remained in
place for 1 second or longer. This test is based on the
natural exploratory or investigatory behaviors of rodents in
a novel “open field” environment. All of the six parameters
are important for evaluation of spontaneous pain and for
comparison of the effects of drug treatment. Changes
in activity may not be reflected by a single parameter;
therefore, each of the six parameters was evaluated in the
comparisons [57,58]. The test chambers were cleaned with
Vindicator disinfectant cleaner (Hillyard, Inc) between
tests to eliminate urine and other olfactory cues from
previous subjects.
Light/dark preference test
A light/dark box with two equally divided compartments
(26x13x28 cm) was used to assess anxiety-like behaviors
of the rats [42,59]. The two chambers were connected
by a 10 × 10 cm doorway in the center of the partition
to allow free access to the adjacent chamber. Rats were
moved into the test room with the test apparatus 30 min
prior to the test. All tests are conducted between 9 am and
11 am. Animals were placed initially in the dark chamber
facing away from the door leading to the adjacent light
chamber; and behaviors were recorded for 10 min (600 s).
The following behavioral parameters were documented: the
number of chamber crossings (light/dark chamber transi-
tion), defined as at least three of the animal’s paws stepping
through the doorway from one chamber to the next; and
total time (sec) spent in the light chamber.
Statistical analysis
The data are expressed as means ±S.E.M. Comparisons
among groups were performed with a One-way analysis
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of variance (ANOVA) followed by Tukey’s multiple com-
parisons post-tests. The time course comparison among
groups was performed with a Two-way ANOVA with
Bonferroni post-tests using GraphPad Prism version
6.0 (GraphPad Software, San Diego California USA).
Two-tailed t-tests were also used where appropriate.
A p ≤ 0.05 was considered significant. Calculation of
the correlation coefficient between tissue HSS and
pain related behaviors was done with the Microsoft
Excel program.
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